FDA declines approval of Summit’s lung cancer treatment
FatCamera/E+ via Getty Images
Summit Therapeutics (SMMT) said Sunday that the U.S. Food and Drug Administration declined to approve ivonescimab combined with chemotherapy for certain patients with advanced lung cancer, citing insufficient evidence that the treatment helps patients live longer.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.